ACR also said "Objective to be cash flow positive by 2022", clearly that is with our funding and not on their own steam
FDA delays = more future capital raise as ACR are not delivering on the development program.
This is extremely disabling and where is dobinsons leadership, asleep at the wheel IMO.
Not sure how they handle this internally but surely the scientists with all the IP will want and go work for a big pharma company that has stability and a record of delivery.
Add to My Watchlist
What is My Watchlist?
